Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 11.5% – Should You Sell?

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s share price dropped 11.5% during trading on Friday. The stock traded as low as $113.71 and last traded at $108.7720. 535,583 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 1,947,136 shares. The stock had previously closed at $122.96.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million, while royalty revenue climbed 44% to a record $341 million. Adjusted EPS of $2.39 also exceeded estimates. Halozyme raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Halozyme Q3 results and raised guidance
• Positive Sentiment: The FDA granted accelerated approval for Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalty revenue. FDA approval announcement
• Positive Sentiment: Halozyme said it expects zero to minimal royalty-revenue impact through at least 2035 from the final Medicare drug-price negotiation rule, easing a potential long-term policy concern. Medicare rule impact update
• Positive Sentiment: Citizens JMP raised its price target to $149 and reiterated a market-outperform rating, reflecting optimism about HALO’s prospects. Citizens JMP rating
• Neutral Sentiment: Wells Fargo raised its target to $110 but maintained an equal-weight rating, signaling a more measured view. Wells Fargo rating
• Negative Sentiment: Despite the earnings beat and higher outlook, the market reaction suggests investors may be scrutinizing the guidance changes. The earnings-call coverage also flagged a Merck patent dispute as a risk to monitor. Q3 earnings call highlights

Analyst Ratings Changes

A number of research firms have weighed in on HALO. HC Wainwright raised their price objective on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Citizens Jmp increased their target price on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the company a “market outperform” rating in a research report on Friday. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $95.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Friday. Finally, TD Cowen boosted their price target on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.09.

Halozyme Therapeutics Trading Down 14.8%

The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The firm has a market capitalization of $11.89 billion, a PE ratio of 31.36, a price-to-earnings-growth ratio of 0.49 and a beta of 0.92. The business’s 50-day moving average price is $115.26 and its 200-day moving average price is $84.57.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.09. The firm had revenue of $492.97 million during the quarter, compared to the consensus estimate of $491.63 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same period last year, the company earned $1.72 earnings per share. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 8.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,230 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the transaction, the director owned 53,609 shares of the company’s stock, valued at $5,818,720.86. This trade represents a 8.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock worth $13,538,046 in the last quarter. Company insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mather Group LLC. increased its position in Halozyme Therapeutics by 48.9% during the 3rd quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 136 shares in the last quarter. North Dakota State Investment Board lifted its holdings in Halozyme Therapeutics by 4.3% in the 3rd quarter. North Dakota State Investment Board now owns 3,598 shares of the biopharmaceutical company’s stock worth $397,000 after buying an additional 147 shares in the last quarter. CoreCap Advisors LLC boosted its holdings in Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 150 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 3.5% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 151 shares during the last quarter. Finally, Twin Capital Management Inc. grew its holdings in Halozyme Therapeutics by 1.4% during the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 161 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.